Cargando…
Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators
Diabetic nephropathy (DN) is one of the most important medical complications in diabetic patients, which is an essential cause of end-stage renal disease in diabetic patients and still lacks effective medicines. Silent information regulator 1 (SIRT1) is closely related to the occurrence and developm...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113817/ https://www.ncbi.nlm.nih.gov/pubmed/33995069 http://dx.doi.org/10.3389/fphar.2021.653233 |
_version_ | 1783690942054662144 |
---|---|
author | Gao, Jian Chen, Qing-Qing Huang, Ye Li, Kai-Hang Geng, Xiao-Ju Wang, Tao Lin, Qi-Si Yao, Ruo-Si |
author_facet | Gao, Jian Chen, Qing-Qing Huang, Ye Li, Kai-Hang Geng, Xiao-Ju Wang, Tao Lin, Qi-Si Yao, Ruo-Si |
author_sort | Gao, Jian |
collection | PubMed |
description | Diabetic nephropathy (DN) is one of the most important medical complications in diabetic patients, which is an essential cause of end-stage renal disease in diabetic patients and still lacks effective medicines. Silent information regulator 1 (SIRT1) is closely related to the occurrence and development of DN. Activation of SIRT1 could significantly improve the symptoms of DN, while the activities of SIRT1 activators need to be further improved. Based on the crystal structure of SIRT1, structure and ligand-based approaches were carried out, and a lead compound 4,456–0661 (renamed as M1) was identified. Moreover, seven M1 analogues (6a-6g) were designed using a structure-based drug design strategy followed by bioactivity evaluation with SRTR2104 used as positive drugs. Among the target molecules, compounds M1, 6b, and 6d were proved to be potent SIRT1 activators, the activities of which are comparable to SRT2104. More importantly, compounds M1, 6b, and 6d could resist high glucose-induced apoptosis of HK-2 cells by activating SIRT1 and deacetylation of p53. Apart from the beneficial effect on apoptosis of DN, these compounds also alleviated high glucose stimulating inflammation response in HK-2 cells through SIRT1/NF-κB (p65) pathway. Consequently, M1, 6b, and 6d could be promising drug candidates for SIRT1 related diseases. |
format | Online Article Text |
id | pubmed-8113817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81138172021-05-13 Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators Gao, Jian Chen, Qing-Qing Huang, Ye Li, Kai-Hang Geng, Xiao-Ju Wang, Tao Lin, Qi-Si Yao, Ruo-Si Front Pharmacol Pharmacology Diabetic nephropathy (DN) is one of the most important medical complications in diabetic patients, which is an essential cause of end-stage renal disease in diabetic patients and still lacks effective medicines. Silent information regulator 1 (SIRT1) is closely related to the occurrence and development of DN. Activation of SIRT1 could significantly improve the symptoms of DN, while the activities of SIRT1 activators need to be further improved. Based on the crystal structure of SIRT1, structure and ligand-based approaches were carried out, and a lead compound 4,456–0661 (renamed as M1) was identified. Moreover, seven M1 analogues (6a-6g) were designed using a structure-based drug design strategy followed by bioactivity evaluation with SRTR2104 used as positive drugs. Among the target molecules, compounds M1, 6b, and 6d were proved to be potent SIRT1 activators, the activities of which are comparable to SRT2104. More importantly, compounds M1, 6b, and 6d could resist high glucose-induced apoptosis of HK-2 cells by activating SIRT1 and deacetylation of p53. Apart from the beneficial effect on apoptosis of DN, these compounds also alleviated high glucose stimulating inflammation response in HK-2 cells through SIRT1/NF-κB (p65) pathway. Consequently, M1, 6b, and 6d could be promising drug candidates for SIRT1 related diseases. Frontiers Media S.A. 2021-04-28 /pmc/articles/PMC8113817/ /pubmed/33995069 http://dx.doi.org/10.3389/fphar.2021.653233 Text en Copyright © 2021 Gao, Chen, Huang, Li, Geng, Wang, Lin and Yao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Gao, Jian Chen, Qing-Qing Huang, Ye Li, Kai-Hang Geng, Xiao-Ju Wang, Tao Lin, Qi-Si Yao, Ruo-Si Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators |
title | Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators |
title_full | Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators |
title_fullStr | Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators |
title_full_unstemmed | Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators |
title_short | Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators |
title_sort | design, synthesis and pharmacological evaluation of naphthofuran derivatives as potent sirt1 activators |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113817/ https://www.ncbi.nlm.nih.gov/pubmed/33995069 http://dx.doi.org/10.3389/fphar.2021.653233 |
work_keys_str_mv | AT gaojian designsynthesisandpharmacologicalevaluationofnaphthofuranderivativesaspotentsirt1activators AT chenqingqing designsynthesisandpharmacologicalevaluationofnaphthofuranderivativesaspotentsirt1activators AT huangye designsynthesisandpharmacologicalevaluationofnaphthofuranderivativesaspotentsirt1activators AT likaihang designsynthesisandpharmacologicalevaluationofnaphthofuranderivativesaspotentsirt1activators AT gengxiaoju designsynthesisandpharmacologicalevaluationofnaphthofuranderivativesaspotentsirt1activators AT wangtao designsynthesisandpharmacologicalevaluationofnaphthofuranderivativesaspotentsirt1activators AT linqisi designsynthesisandpharmacologicalevaluationofnaphthofuranderivativesaspotentsirt1activators AT yaoruosi designsynthesisandpharmacologicalevaluationofnaphthofuranderivativesaspotentsirt1activators |